Mobile Health Tool for Asthma
(AIM2ACT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a mobile health tool called AIM2ACT to help manage asthma in early adolescents. The goal is to determine if this tool effectively supports asthma management by involving caregivers and guiding families in handling asthma together. Participants are children aged 12-15 with poorly controlled asthma, meaning they experience frequent symptoms or disruptions in daily life due to asthma. The trial compares AIM2ACT to another mobile health condition, the mHealth Attention Control Condition, to evaluate which works better. Participants must live with a caregiver and have a recent history of asthma issues. As an unphased trial, this study offers participants the chance to contribute to innovative research that could improve asthma management for families.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop your current medications. However, since it mentions that participants must have an active inhaled corticosteroid prescription, it seems likely that you can continue your current asthma medications.
What prior data suggests that this mobile health tool is safe for adolescents with asthma?
Research shows no specific safety information is available for AIM2ACT, the mobile health tool tested to help manage asthma in teenagers. The trial's "Not Applicable" phase label indicates that AIM2ACT is not a drug but likely involves behavioral methods or technology, which typically carry different risks than medication trials.
Mobile health tools like AIM2ACT generally aim to improve asthma management and increase caregiver involvement. They are usually considered low-risk compared to medications because they don't involve ingesting substances. The research provided reports no negative effects related to AIM2ACT. Prospective participants should discuss any concerns with study coordinators or their healthcare provider.12345Why are researchers excited about this trial?
Researchers are excited about AIM2ACT because it offers a new way to manage asthma by using mobile health technology. Unlike traditional treatments that often focus solely on medication, AIM2ACT is designed to enhance collaboration between caregivers and patients, guiding them through asthma management together. This approach not only involves caregivers more actively but also leverages technology to provide real-time support and monitoring, which is different from the usual reliance on periodic doctor visits and self-reported symptoms. By integrating caregivers into the management process, AIM2ACT aims to improve overall asthma care and outcomes.
What evidence suggests that AIM2ACT is effective for asthma?
Research shows that AIM2ACT, which participants in this trial may receive, can significantly help teens manage their asthma. Teens who used AIM2ACT demonstrated improved asthma control compared to those who did not. These improvements were evident and made a real difference in managing asthma. AIM2ACT involves caregivers and supports teens in managing their condition. This mobile health tool has shown promise in improving life for teens with poorly controlled asthma.14678
Who Is on the Research Team?
Sreekala Prabhakaran, M.D.
Principal Investigator
University of Florida
Are You a Good Fit for This Trial?
This trial is for early adolescents aged 12-15 with poorly controlled asthma and their caregivers (18-70 years old). Participants must speak English, live with the caregiver, and have experienced recent frequent asthma symptoms or have a history of severe asthma events. Adolescents should be on inhaled corticosteroids and diagnosed with asthma.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the AIM2ACT mHealth intervention or mHealth attention control condition
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AIM2ACT
- mHealth Attention Control Condition
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator